FDA Says Celgene's Revlimid Tied To Higher Cancer Risks
The U.S. Food and Drug Administration said Monday that some newly diagnosed patients who received Celgene Corp.'s blood cancer treatment drug Revlimid are at an increased risk of developing certain new...To view the full article, register now.
Already a subscriber? Click here to view full article